HC Wainwright reiterated their buy rating on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a report released on Tuesday. The brokerage currently has a $13.00 price target on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on INO. Maxim Group restated a buy rating and issued a $12.00 price target on shares of Inovio Pharmaceuticals in a research note on Tuesday. ValuEngine upgraded Inovio Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 11th. BidaskClub upgraded Inovio Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday. Stifel Nicolaus restated a buy rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a research note on Thursday, May 25th. Finally, Citigroup Inc. began coverage on Inovio Pharmaceuticals in a research note on Wednesday, September 6th. They issued a buy rating and a $10.00 price target for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $19.80.
Shares of Inovio Pharmaceuticals (NASDAQ INO) opened at 6.00 on Tuesday. The stock has a 50 day moving average price of $5.69 and a 200 day moving average price of $6.69. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86. The company’s market capitalization is $541.36 million.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s quarterly revenue was up 229.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) EPS. On average, analysts predict that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.
WARNING: This piece was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2888383/inovio-pharmaceuticals-inc-ino-given-buy-rating-at-hc-wainwright.html.
Large investors have recently added to or reduced their stakes in the company. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at $107,000. PNC Financial Services Group Inc. raised its holdings in shares of Inovio Pharmaceuticals by 5.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth $171,000. OxFORD Asset Management LLP acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth $194,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth $197,000. Hedge funds and other institutional investors own 24.83% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.